HB 1329: Controlled substances; Schedule I; provide certain provisions

House Bill 1329 (AS PASSED HOUSE AND SENATE)

By: Representatives Stephens of the 164th and Newton of the 127th

A BILL TO BE ENTITLED

AN ACT

To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, so as to provide for certain provisions relating to Schedule I controlled substances; to provide for certain provisions relating to the definition of dangerous drugs; to provide for related matters; to provide for an effective date; to repeal conflicting laws; and for other purposes.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

SECTION 1.

Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, is amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising subparagraph (E) of paragraph (16) as follows: "(E) By substitution at the 5-position or 6-position with a nitro, alkyl, halide, cyano, or acetyl group or primary amine;"

SECTION 2.

Said chapter is further amended in Code Section 16-13-71, relating to dangerous drug, by adding new paragraphs to subsection (b) to read as follows: "(1.5) Aceclidine;" "(12.7) Acoltremon;" "(17.2) Aficamten;" "(68.45) Atrasentan;" "(69.21) Avutometinib;" "(91.71) Berahyaluronidase alfa-pmph;" "(106.4) Brensocatib;" "(196.3) Clesrovimab-cfor;" "(240.97) Datopotamab deruxtecan-dlnk;" "(243.4) Defactinib;" "(244.7) Delgocitinib;" "(248.5) Depemokimab-ulaa;" "(316.6) Donidalorsen;" "(317.15) Dordaviprone;" "(318.7) Doxecitine;" "(320.5) Doxribtimine;" "(331.0513) Elamipretide;" "(331.0555) Elinzanetant;" "(379.8) Etripamil;" "(386.95) Fitusiran;" "(411.9) Garadacimab-gxii;" "(414.4) Gepotidacin;" "(466.7) Imlunestrant;" "(513.75) Lerodalcibep-liga;" "(523.5) Linvoseltamab-gcpt;" "(619.15) Mirdametinib;" "(640.105) Nerandomilast;" "(644.605) Nipocalimab-aahu;" "(663.65) Onasemnogene abeparvovec-brve;" "(681.65) Paltusotine;" "(698.5) Penpulimab-kcqx;" "(742.7) Plozasiran;" "(768.6) Prademagene zamikeracel;" "(832.975) Remibrutinib;" "(836.6) Revakinagene taroretcel-lwey;" "(842.3) Rilzabrutinib;" "(852.055) Sebetralstat;" "(855.1) Sepiapterin;" "(855.735) Sevabertinib;" "(855.83) Sibeprenlimab-szsi;" "(927.8) Sunvozertinib;" "(929.7) Suzetrigine;" "(930.978) Taletrectinib;" "(931.565) Telisotuzumab vedotin-tllv;" "(974.65) Treosulfan;" "(1030.9) Vimseltinib;" "(1042.2) Ziftomenib;" "(1042.85) Zoliflodacin;" "(1042.91) Zongertinib;" "(1042.93) Zopapogene imadenovec-drba;"

SECTION 3.

Said chapter is further amended in subsection (b) of said Code section by repealing and reserving paragraph (324) and by revising paragraphs (60.3), (160.5), and (217.2) as follows: "(60.3) Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl;" "(160.5) Chikungunya vaccine, Live;" "(217.2) COVID-19 Vaccine, mRNA;"

SECTION 4.

Said chapter is further amended in subsection (c) of said Code section by revising paragraph

(9.33) as follows:

"(9.33) Epinephrine —:

(A) When when used in a device that delivers a metered spray of 0.125 mg. of epinephrine or less to provide temporary relief for symptoms of mild, intermittent asthma and is a product in finished dosage formulation in its original container that has been approved by and labeled in compliance with the U.S. Food and Drug Administration (FDA); and

(B) When distributed by a pharmacist as provided by the State Board of Pharmacy, in a device that delivers a spray of 2 mg. of epinephrine or less to provide emergency treatment of allergic reactions, including anaphylaxis, and is a product in finished dosage formulation in its original container that has been approved by and labeled in compliance with the U.S. Food and Drug Administration (FDA);"

SECTION 5.

This Act shall become effective upon its approval by the Governor or upon its becoming law without such approval.

SECTION 6.

All laws and parts of laws in conflict with this Act are repealed.